VEGF and MMP-9: biomarkers for canine lymphoma

被引：25

作者：

Aresu, L. ^{[1
]}

Arico, A. ^{[1
]}

Comazzi, S. ^{[2
]}

Gelain, M. E. ^{[2
]}

Riondato, F. ^{[3
]}

Mortarino, M. ^{[2
]}

Morello, E. ^{[3
]}

Stefanello, D. ^{[4
]}

Castagnaro, M. ^{[1
]}

机构：

[1] Univ Padua, Fac Vet Med, Dept Publ Hlth Comparat Pathol & Vet Hyg, I-35020 Legnaro, Italy

[2] Univ Milan, Fac Vet Med, Dept Anim Pathol Publ Hlth & Vet Hyg, Milan, Italy

[3] Univ Torino, Fac Vet Med, Dept Anim Pathol, Grugliasco, TO, Italy

[4] Univ Milan, Fac Vet Med, Dept Vet Sci, Milan, Italy

来源：

VETERINARY AND COMPARATIVE ONCOLOGY | 2014年 / 12卷 / 01期

关键词：

ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; FACTOR-BETA; CELL-GROWTH; EXPRESSION; DOGS; MATRIX-METALLOPROTEINASE-9; ANGIOGENESIS; CORRELATE; SUBTYPES;

D O I：

10.1111/j.1476-5829.2012.00328.x

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

Vascular endothelial growth factor (VEGF) and metalloproteinase (MMP) 2 and 9 are useful biomarkers in human lymphoma. During cancerogenesis, transforming growth factor beta (TGF-β) stimulates VEGF and MMPs production. VEGF and TGF-β plasma levels were tested by ELISA, MMP-2 and MMP-9 by gelatine zymography in 37 dogs with lymphoma, 13 of which were also monitored during chemotherapy. Ten healthy dogs served as control. Lymphoma dogs showed higher act-MMP-9 (P<0.01) and VEGF (P<0.05), and lower TGF-β than controls, and a positive correlation between act-MMP-9 and VEGF (P<0.001). Act-MMP-9 and VEGF were significantly higher in T-cell lymphomas, and in stage V compared with stages III-IV disease, regardless of immunophenotype. VEGF was higher in high-grade compared with low-grade T-cell lymphomas. No correlation was found between cytokines levels at presentation and outcome. During chemotherapy, act-MMP-9 and VEGF decreased in B-cell lymphomas (P<0.01), suggesting a possible predictive role in this group of dogs. © 2012 John Wiley & Sons Ltd.

引用

页码：29 / 36

页数：8

共 33 条

[1] Matrix metalloproteinases and their inhibitors in canine mammary tumors
Aresu, Luca
Giantin, Mery
Morello, Emanuela
Vascellari, Marta
Castagnaro, Massimo
Lopparelli, Rosa
Zancanella, Vanessa
Granato, Anna
Garbisa, Spiridione
Arico, Arianna
Bradaschia, Alice
Mutinelli, Franco
Dacasto, Mauro
[J]. BMC VETERINARY RESEARCH, 2011, 7 : 33
[2] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G
Brekken, R
McMahon, G
Vu, TH
Itoh, T
Tamaki, K
Tanzawa, K
Thorpe, P
Itohara, S
Werb, Z
Hanahan, D
[J]. NATURE CELL BIOLOGY, 2000, 2 (10) : 737 - 744
[3] BLAY JY, 1993, BLOOD, V82, P2169
[4] Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans - man and his best friend share more than companionship
Breen, Matthew
Modiano, Jaime F.
[J]. CHROMOSOME RESEARCH, 2008, 16 (01) : 145 - 154
[5] DAVIES B, 1993, CANCER RES, V53, P5365
[6] Role of transforming growth factor-β in hematologic malignancies
Dong, Mei
Blobe, Gerard C.
[J]. BLOOD, 2006, 107 (12) : 4589 - 4596
[7] New functions for the matrix metalloproteinases in cancer progression
Egeblad, M
Werb, Z
[J]. NATURE REVIEWS CANCER, 2002, 2 (03) : 161 - 174
[8] The biology of VEGF and its receptors
Ferrara, N
Gerber, HP
LeCouter, J
[J]. NATURE MEDICINE, 2003, 9 (06) : 669 - 676
[9] Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry
Gelain, M. E.
Mazzilli, M.
Riondato, F.
Marconato, L.
Comazzi, S.
[J]. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2008, 121 (3-4) : 179 - 188
[10] Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma- affected dogs
Gentilini, F
Calzolari, C
Turba, ME
Agnoli, C
Fava, D
Forni, M
Bergamini, PF
[J]. LEUKEMIA RESEARCH, 2005, 29 (11) : 1263 - 1269

← 1 2 3 4 →